Physician profile
Amy Caroline Sapp
NPI 1720073711
$9,184.41
in general payments reported to CMS, 2019-2025
55 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $1,235 · 2021: $1,767 · 2022: $1,635 · 2023: $1,384 · 2024: $1,196 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,672.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,008.57 | 2019-2025 | |
| Novo Nordisk INC | $1,005.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $822.45 | 2019-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $810.59 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $567.80 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $435.54 | 2019-2025 | Farxiga, Fasenra, Airsupra |
| Dexcom, INC. | $337.97 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.33 | 2019-2024 | Jardiance, Synjardy |
| Astellas Pharma US INC | $305.45 | 2019-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $252.81 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $248.71 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $247.71 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $246.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $238.72 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $190.98 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Sapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.